OUR PIPELINE
MS
| REGIMEN | DIsease | Preclinical | Phase 1 | Phase 2 | Phase 3 | Registration Status | Learn More | |
|---|---|---|---|---|---|---|---|---|
|
Single Agent |
Ublituximab monotherapy: anti-CD20 mAb | Relapsing MS |
ULTIMATE I and II
|
 |
||||
| Umbralisib monotherapy: P13k-delta & CK1-epsilon inhibitor | R/R MZL |
UNITY-NHL
|
PDUFA: 2/15/2021 | |
||||
| Umbralisib monotherapy | R/R FL |
UNITY-NHL
|
PDUFA: 6/15/2021 | |
||||
|
Combination |
Umbralisib + ublituximab (U2) | R/R NHL |
UNITY-NHL
|
|
||||
| Umbralisib + ublituximab (U2) | TN and R/R CLL |
UNITY-CLL
|
|
|||||
| Ublituximab + ibrutinib | R/R high-risk CLL |
GENUINE
|
|
|||||
| Umbralisib + ublituximab + venetoclax | TN and R/R CLL |
ULTRA-V
|
|
|||||
| Umbralisib + ublituximab + TG-1701 (BTKi) | TN and R/R CLL & NHL | |
||||||
|
Early Pipeline |
Cosibelimab (TG-1501): anti-PD-L1 mAb | B-cell malignancies | |
|||||
| TG-1701: BTK inhibitor | B-cell malignancies | |
||||||
| TG-1801: anti-CD47/CD19 bispecific mAb | B-cell malignancies | |
||||||
| TG-1601: BET inhibitor | B-cell malignancies | |
||||||
|
ENROLLMENT COMPLETED
ENROLLMENT ONGOING
|
||||||||
R/R=relapsed or refractory; TN=treatment naive.
|
ENROLLMENT COMPLETED
ENROLLMENT ONGOING
|
|||||
|---|---|---|---|---|---|
|
Single Agent |
|||||
| REGIMEN | Preclinical | Phase 1 | Phase 2 | Phase 3 | |
|
MS |
Ublituximab monotherapy: anti-CD20 mAb
DiseaseRelapsing MS Learn More |
ULTIMATE I and II
|
|||
|
ONCOLOGY
|
Umbralisib monotherapy: P13k-delta & CK1 -epsilon inhibitor
DiseaseR/R MZL Learn More |
UNITY-NHL
PDUFA: 2/15/2021 |
|||
|
Umbralisib + Ublituximab (U2)
DiseaseR/R FL Learn More |
UNITY-NHL
PDUFA: 6/15/2021 |
||||
|
COMBINATION |
|||||
|---|---|---|---|---|---|
| REGIMEN | Preclinical | Phase 1 | Phase 2 | Phase 3 | |
|
ONCOLOGY
|
Umbralisib + ublituximab (U2)
DiseaseR/R NHL Learn More |
UNITY-NHL
|
|||
|
Umbralisib + ublituximab (U2)
DiseaseTN and R/R CLL Learn More |
UNITY-CLL
|
||||
|
Ublituximab + ibrutinib
DiseaseR/R high-risk CLL Learn More |
GENUINE
|
||||
|
Umbralisib + ublituximab + venetoclax
DiseaseTN and R/R CLL Learn More |
ULTRA-V
|
||||
|
Umbralisib + ublituximab + TG-1701 (BTKi)
DiseaseTN and R/R CLL & NHL Learn More |
|
||||
|
EARLY PIPELINE |
||||||
|---|---|---|---|---|---|---|
| REGIMEN | Preclinical | Phase 1 | Phase 2 | Phase 3 | ||
|
ONCOLOGY
|
Cosibelimab (TG-1501): anti-PD-L1 mAb
DiseaseB-cell malignancies Learn More |
|||||
|
TG-1701: BTK inhibitor
DiseaseB-cell malignancies Learn More |
||||||
|
TG-1801: anti-CD47/CD19 bispecific mAb
DiseaseB-cell malignancies Learn More |
||||||
|
TG-1601: BET inhibitor
DiseaseB-cell malignancies Learn More |
||||||
|
R/R=relapsed or refractory; TN=treatment naive. The safety and efficacy of our investigational compounds have not been established. These products have not been approved by the US Food and Drug Administration or other regulatory authorities. |
||||||